synthesize

{
  "ranked_hypotheses": [
    {
      "title": "LRP1-mediated tau uptake disruption as an initiator of early tau propagation requires proximal validation",
      "description": "The debate supports carrying forward LRP1-mediated tau uptake disruption as an initiator of early tau propagation only if a proximal endpoint changes before the late outcome. The decisive validation path is: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts.",
      "target_gene": "LRP1",
      "dimension_scores": {
        "evidence_strength": 0.57,
        "novelty": 0.64,
        "feasibility": 0.69,
        "therapeutic_potential": 0.58,
        "mechanistic_plausibility": 0.67,
        "druggability": 0.5,
        "safety_profile": 0.55,
        "competitive_landscape": 0.55,
        "data_availability": 0.63,
        "reproducibility": 0.66
      },
      "composite_score": 0.604,
      "evidence_for": [
        {
          "claim": "Preregistered claim: LRP1-mediated tau uptake disruption in neurons initiates the earliest tau propagation cascade; blocking LRP1 prevents downstream spreading",
          "source": "AD-MASTER-PLAN-LRP1-20260428030757"
        }
      ],
      "evidence_against": [
        {
          "claim": "LRP1 has broad vascular and lipid roles, so blocking uptake may trade tau reduction for impaired clearance or vascular toxicity",
          "source": "AD-MASTER-PLAN-LRP1-20260428030757"
        }
      ]
    },
    {
      "title": "Stratified falsifiers should govern AD Master Plan preregistration: LRP1",
      "description": "Claims from this analysis should be evaluated across LRP1, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.",
      "target_gene": "AD",
      "dimension_scores": {
        "evidence_strength": 0.54,
        "novelty": 0.59,
        "feasibility": 0.74,
        "therapeutic_potential": 0.5,
        "mechanistic_plausibility": 0.61,
        "druggability": 0.43,
        "safety_profile": 0.59,
        "competitive_landscape": 0.53,
        "data_availability": 0.68,
        "reproducibility": 0.7
      },
      "composite_score": 0.591,
      "evidence_for": [
        {
          "claim": "The analysis question names specific entities or evaluation structure.",
          "source": "AD-MASTER-PLAN-LRP1-20260428030757"
        }
      ],
      "evidence_against": [
        {
          "claim": "The current record can still be confounded by stage, leakage, or artifact effects.",
          "source": "AD-MASTER-PLAN-LRP1-20260428030757"
        }
      ]
    },
    {
      "title": "LRP1 should remain under review until replicated",
      "description": "The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.",
      "target_gene": "tau",
      "dimension_scores": {
        "evidence_strength": 0.52,
        "novelty": 0.55,
        "feasibility": 0.71,
        "therapeutic_potential": 0.52,
        "mechanistic_plausibility": 0.58,
        "druggability": 0.45,
        "safety_profile": 0.58,
        "competitive_landscape": 0.52,
        "data_availability": 0.65,
        "reproducibility": 0.69
      },
      "composite_score": 0.577,
      "evidence_for": [
        {
          "claim": "Concrete next test: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts",
          "source": "AD-MASTER-PLAN-LRP1-20260428030757"
        }
      ],
      "evidence_against": [
        {
          "claim": "Promotion before replication would weaken quality control.",
          "source": "AD-MASTER-PLAN-LRP1-20260428030757"
        }
      ]
    }
  ],
  "knowledge_edges": [
    {
      "source_id": "AD-MASTER-PLAN-LRP1-20260428030757",
      "source_type": "analysis",
      "target_id": "LRP1",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-LRP1-20260428030757",
      "source_type": "analysis",
      "target_id": "AD",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-LRP1-20260428030757",
      "source_type": "analysis",
      "target_id": "tau",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-LRP1-20260428030757",
      "source_type": "analysis",
      "target_id": "amyloid",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    }
  ],
  "synthesis_summary": "Consensus: AD Master Plan preregistration: LRP1 is substantive enough for debate because it names LRP1-mediated tau uptake disruption as an initiator of early tau propagation and can be tied to a concrete validation path: cell-type-specific LRP1 perturbation with live tau uptake, trans-synaptic spread, and vascular safety readouts. Dissent: LRP1 has broad vascular and lipid roles, so blocking uptake may trade tau reduction for impaired clearance or vascular toxicity. The claim should remain under review until the falsifier or replication path is executed."
}